Legendary Genetics (LEGN.US) CAR-T therapy single infusion helps multiple myeloma patients remain disease-free for five years.

According to the Wise Finance APP, on June 3rd, Legend Biotech (LEGN.US) announced the latest long-term follow-up data from the CARTITUDE-1 study in patients with relapsed or refractory multiple myeloma (RRMM) in Somerset, New Jersey, USA. These RRMM patients received only a single infusion of CARVYKTI (Cilta-cel) and did not receive maintenance therapy or subsequent myeloma treatment. It is worth noting that 33% (32/97) of the patients had not experienced disease progression for five years or longer.